PO.SHP01.02 · 科学与健康政策
基于案例的教育如何提升转移性乳腺癌管理的临床表现：一项关于 TROP2 靶向抗体药物偶联物的研究
How case based education elevated clinical performance in metastatic breast cancer management: A study for TROP2 directed antibody drug conjugates
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：转移性乳腺癌（mBC）的治疗格局随抗体药物偶联物（ADC）的出现而进步，尤其是 TROP2 靶向药物 sacituzumab govitecan 和 datopotamab deruxtecan。这些选择为 HER2- mBC 患者扩展了治疗潜力。然而，快速更新给临床医生采用循证、个体化策略带来了挑战。
目的：评估一项数字化、基于案例的短篇 CME 活动能否弥补关于 TROP2 靶向 ADC 在 HER2- mBC 中循证使用的知识与能力（K/C）差距。
方法：一项 15 分钟、基于案例、经认证的在线活动（“个体化诊疗的机遇：论证 TROP2 靶向 ADC 在 HR+、HER2- mBC 中的应用”）于 2025 年 3 月 28 日上线。全球学术界和社区肿瘤科医生完成了测量 K/C 结果的前/后测评。上线 4 周后的定性随访问卷评估了实践变化和实施行为。
结果：截至 2025 年 6 月 3 日，共有 4,073 名学习者参与。活动后数据显示 K/C 分数平均提高 20%。参与者在识别合适患者以及按临床证据应用 ADC 方面有显著改善。基线知识最薄弱的领域——患者识别——显示出明显进步，尽管进一步强化可能优化其在实践中的影响。值得注意的是，73% 的人报告了归因于该活动的实践变化。教育后评估显示个体化和循证治疗决策以及不良事件管理的实施有所增加（表 1）。
结论：这项基于案例的 CME 活动有效提升了临床医生关于 TROP2 靶向 ADC 用于 HER2- mBC 的 K/C，并支持了持续的实践改变。个体化、数字化的教育形式可能加速新近可用和新兴疗法融入肿瘤诊疗。
表 1：教育对实践改变的影响 实践改变 初始分析，%；n=33 参与后 4 周随访，%；N=55 识别适合接受 TROP2 靶向 ADC 的 HR+、HER2 阴性 mBC 合适患者 58 71 认识适当特征以在 HR+、HER2 阴性 mBC 患者的 ADC 之间进行选择 64 85 主动实施最佳实践以管理接受 TROP2 靶向 ADC 的 mBC 患者的 AE 39 69 应用指南推荐为 HR+、HER2 阴性转移性乳腺癌患者选择 TROP2 靶向 ADC 48 56
查看英文原文 English abstract
Background: The treatment landscape of metastatic breast cancer (mBC) has advanced with antibody-drug conjugates (ADCs), notably the TROP2-directed agents sacituzumab govitecan and datopotamab deruxtecan. These options have extended treatment potential for patients with HER2- mBC. However, rapid updates pose challenges for clinicians in adopting evidence-based, personalized strategies.
Objective: To assess whether a digital, case-based, short-format CME activity could address knowledge and competence (K/C) gaps regarding the evidence-based use of TROP2-directed ADCs in HER2- mBC.
Methods: A 15-minute, case-based, accredited online activity (“Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- mBC”) launched March 28, 2025. Global academic and community oncologists completed pre-/post-assessments measuring K/C outcomes. A qualitative follow-up questionnaire, 4 weeks post-launch, evaluated practice changes and implementation behaviors.
Results: As of June 3, 2025, 4,073 learners participated. Post-activity data showed a 20% mean improvement in K/C scores. Participants improved notably in identifying appropriate patients and applying ADCs in alignment with clinical evidence. The lowest baseline knowledge area-patient identification-showed marked gains, though further reinforcement may optimize impact in practice. Notably, 73% reported practice changes attributable to the activity. Post-education assessment revealed increased implementation of personalized and evidence-based treatment decision-making and adverse event management (Table 1).
Conclusion: This case-based CME activity effectively improved clinician K/C regarding TROP2-directed ADCs for HER2- mBC and supported sustained practice change. Personalized, digital education formats may accelerate integration of newly available and emerging therapies into oncology care.
Table 1: Impact of Education on Practice Change Change in practice Initial analysis, %; n=33 4 week F/U after participation, %; N=55 Identify appropriate patients with HR+, HER2-negative mBC who are candidates for TROP2-directed ADCs 58 71 Recognize appropriate characteristics to select between ADCs for patients with HR+, HER2-negative mBC 64 85 Proactively implement best practices to manage AEs for patients with mBC on TROP2-directed ADCs 39 69 Apply guideline recommendations to select TROP2 directed ADCs for patients with HR+, HER2-negative metastatic breast cancer 48 56
利益披露 Disclosure
M. Coulehan, None..
S. Welch, None..
L. Anantharaman, None..
E. Kitterman, None..
A. Suhail, None.